Inactief instrument

Andere talen OXIS International, Inc. Other OTC

Aandelen

US6918294025

slotkoers Other OTC Andere beurzen
- ^USD	-

20/05	Top premarket stijgers	MT
26/03	GT Biopharma, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Top Premarket Gainers	20/05
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	15/05
Caterpillar deja París, el cacao está menos caliente	30/04
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud	30/04
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	26/03
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	01/02
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	01/02
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	07/12
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	06/12
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	07/11
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	06/11
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	06/11
GT Biopharma Reports Third Quarter 2023 Financial Results	01/11
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	23-08-23
GT Biopharma Reports Second Quarter 2023 Financial Results	07-08-23
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen OXIS International, Inc. Other OTC

Aandelen

US6918294025

Andere talen

Filters